24/7 Market News Snapshot 18 December, 2024 – Quoin Pharmaceuticals, Ltd. American Depositary Shares (NASDAQ:QNRX)

December 18, 2024

DENVER, Colo., 18 December, 2024 (247marketnews.com) – (NASDAQ:QNRX) are discussed in this article.
Quoin Pharmaceuticals, Ltd. is demonstrating a positive trend in pre-market trading, currently priced at $0.631, which marks a significant rise of 4.71% from the previous close of $0.603. The trading volume has reached an impressive 3.69 million shares, indicative of heightened investor interest. This upward trajectory suggests a potential shift in momentum, possibly influenced by favorable market sentiment or recent developments within the company. Observing patterns in volume and technical indicators will be crucial for investors seeking confirmation of this trend, especially if the stock continues to breach key resistance levels.

In parallel, Quoin Pharmaceuticals has announced promising interim results from clinical studies targeting Netherton Syndrome. The company’s investigational treatment, QRX003, has shown remarkable effectiveness, with interim data revealing significant improvements in skin conditions among study participants. In an open-label study, subjects experienced a reduction in the Modified Ichthyosis Area of Severity Index (MIASI) from 18 to 4 following six weeks of twice-daily dosing. Additionally, assessments made by investigators indicated a shift in disease severity from ‘moderate’ to ‘mild,’ alongside a notable decline in itch severity.

Further encouraging results were reported from Quoin’s 12-week Investigator Pediatric Study, where treatment with QRX003 led to significant enhancements in skin appearance within just 12 days. The Investigator’s Global Assessment ratings shifted dramatically from ‘severe’ to ‘mild-moderate,’ indicating QRX003’s strong potential as a rapid treatment option for affected children.

Dr. Michael Myers, CEO of Quoin Pharmaceuticals, expressed optimism regarding these developments, reiterating the company’s commitment to providing effective treatments for the Netherton Syndrome community. As the company continues its clinical trials, it aims to explore new therapeutic avenues for rare and orphan diseases, striving to improve the quality of life for patients.

Related news for (QNRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.